Relapsed and/or Refractory Multiple Myeloma Clinical Trials

33 clinical trials for Relapsed and/or Refractory Multiple Myeloma across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• 18F-Fluciclovine PET/CT in Multiple Myeloma — RECRUITING · PHASE2
• A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) — RECRUITING · PHASE3
• A non-interventional study of melphalan flufenamide (melflufen, Pepaxti) in combination with dexamethasone in patients with relapsed and/or refractory multiple myeloma (RRMM) according to the approved label. — RECRUITING
• A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma — RECRUITING · PHASE1
• OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM — RECRUITING · PHASE1
• Oral Oprozomib in combination with oral dexamethasone in Relapsed and/or Refractory Multiple Myeloma — COMPLETED · PHASE2
• Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma — SUSPENDED · PHASE1
• A Phase 1 Study of BMS-986453 in Participants with Relapsed and/or Refractory Multiple Myeloma — TERMINATED · PHASE1
• A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) — WITHDRAWN · PHASE1
• ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma — TERMINATED · PHASE1
• Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma — TERMINATED · PHASE1
• Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex — ACTIVE_NOT_RECRUITING · PHASE1
• A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM) — TERMINATED · PHASE1
• A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) - ALUMMINATE RRMM — OTHER · PHASE3
• Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma — OTHER · PHASE1
• A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma — TERMINATED · PHASE1
• A Phase 1b/2a, Multicenter, Open-Label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Alnuctamab in Combination with Mezigdomide in Participants with Relapsed and/or Refractory Multiple Myeloma — OTHER · PHASE2
• A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone — COMPLETED
• Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia — OTHER · NA
• This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma. — OTHER · PHASE1
• A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma — COMPLETED · PHASE2
• A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy — COMPLETED · PHASE4
• Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain. — OTHER
• A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple Myeloma — OTHER · NA
• Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple Myeloma — OTHER
• A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma — COMPLETED · PHASE2
• A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma — COMPLETED · PHASE1
• A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) — TERMINATED · PHASE1
• The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM) — COMPLETED · PHASE2
• Quality of Life, Symptoms and Treatment Satisfaction in Adult Patients With Relapsed and/or Refractory Multiple Myeloma, Receiving Ixazomib (Ninlaro®) in Combination With Lenalidomide and Dexamethasone in a Real World Setting: Pilot Study — OTHER
• Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma — OTHER · PHASE2
• Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — COMPLETED · PHASE2
• Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma — COMPLETED · PHASE1

Refine this search